What is Optimi Health Corp.'s (OPTI.CN) StockRank?

MoatMap's StockRank for Optimi Health Corp. (OPTI.CN) is 2/100, with a Strong Sell signal. This is a composite score combining Quality (14), Value (22), and Momentum (31) factor ranks across MoatMap's 20,000+ stock universe.

Does Optimi Health Corp. have an economic moat?

Optimi Health Corp. (OPTI.CN) has a Quality factor score of 14/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Optimi Health Corp. a buy, hold, or sell?

MoatMap's current signal for Optimi Health Corp. (OPTI.CN) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Optimi Health Corp. in?

Optimi Health Corp. (OPTI.CN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

OPTI.CN

STRONG SELLREMOVE

Optimi Health Corp. · Healthcare · Canada · $25M · Avg Vol: $56K/d

StockRank

P/E (TTM)

—

ROE

-88.7%

D/E

1.9x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Optimi Health is a micro-cap life sciences company focused on psychedelics, lacking any established commercial scale, recurring revenue, or durable economic moat. It fails every single quality and scale metric required by our investment philosophy, representing a highly speculative venture rather than an asymmetric compounder.

COMPANY DESCRIPTION

Optimi Health Corp. is a life sciences company licensed to cultivate, extract, and formulate functional mushrooms and natural psychedelic compounds for clinical trials and therapeutic use. The company's competitive moat is anchored by its state-of-the-art, EU-GMP compliant production facilities in British Columbia, which ensure pharmaceutical-grade quality control. It operates as a specialized niche manufacturer positioned to supply the emerging global market for psychedelic-assisted psychotherapy and natural wellness products.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	56,965	0.1M	0.3M	0.3M	74.1%
EPS	-0.91	-1.27	-1.48	-0.85	—
Shares	5.6M	2.9M	3.2M	3.2M	-42.7%
Debt	0.1M	1.2M	1.9M	4.6M	245.9%
Equity	11.3M	9.3M	6.8M	4.6M	-25.7%
Op CF	-3.2M	-2.5M	-3.0M	-1.9M	—
Inv CF	-2.2M	-0.5M	-0.1M	-62,370	—
Fin CF	0.8M	2.7M	2.3M	2.7M	—

PRICE (1Y)-38.6%

SMA 50SMA 200

$4.09

RSI (14)

45.0

52W High

$8.89

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-47.3%15.4

ROE

-88.7%9.2

GP/Assets

-0.8%8.6

Op. Margin

-1033.7%7.0

FCF/Assets

-3.9%37.9

Piotroski

430.1

Int. Cover

-6.0x27.4

D/E Ratio

1.86x6.3

Current Ratio

0.06x0.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-8.7x25.0

P/FCF

—N/A

P/B

6.6x18.9

P/S

176.9x5.3

Div Yield

—N/A

Momentum

52W High %

46%20.7

RS 6M

-52%21.8

SMA 50/200

0.90x38.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+63%59.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$25M

P/E (Forward)

-11.4x

Gross Margin

-55.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OPTI.CN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
OPTI.CN	Optimi Health Corp.(you)	$25M	2	STRONG SELL
LEEF.CN	Leef Brands Inc.	$46M	29	SELL
NVRS.CN	Noveris Health Sciences Inc.	$64M	23	SELL
CRDL	Cardiol Therapeutics Inc.	$122M	20	SELL
OGI	Organigram Global Inc.	$138M	31	SELL
TLRY	Tilray Brands, Inc.	$576M	7	STRONG SELL
ACB.TO	Aurora Cannabis Inc.	$180M	30	SELL
DB.V	Decibel Cannabis Company Inc.	$50M	60	HOLD
CGC	Canopy Growth Corporation	$440M	18	STRONG SELL
HLS.TO	HLS Therapeutics Inc.	$100M	63	HOLD

Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 35.6%

Optimi Health Corp. (OPTI.CN) — Stock Score Summary

Optimi Health Corp. (OPTI.CN) has a MoatMap StockRank of 2/100 based on Quality (14/100), Value (22/100), and Momentum (31/100) factor scores. The current signal is STRONG SELL. Optimi Health is a micro-cap life sciences company focused on psychedelics, lacking any established commercial scale, recurring revenue, or durable economic moat. It fails every single quality and scale metric required by our investment philosophy, representing a highly speculative venture rather than an asymmetric compounder.

Key Financial Metrics

Price	$4.09
Market Cap	$25M
P/E (Forward)	-11.39
Price/Book	6.63
Return on Equity	-88.7%
Return on Invested Capital	-47.3%
Debt/Equity	185.66
Gross Margin	-55.2%
Operating Margin	-1033.7%
Revenue Growth	62.5%
Free Cash Flow	$-425K

Optimi Health Corp. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Optimi Health Corp.’s (OPTI.CN) StockRank?: MoatMap’s StockRank for Optimi Health Corp. (OPTI.CN) is 2/100, with a Strong Sell signal. It is a composite of Quality (14), Value (22), and Momentum (31) factor ranks across MoatMap’s 20,000+ stock universe.
Does Optimi Health Corp. have an economic moat?: Optimi Health Corp. (OPTI.CN) has a Quality factor score of 14/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Optimi Health Corp. a buy, hold, or sell?: MoatMap’s current signal for Optimi Health Corp. (OPTI.CN) is Strong Sell, based on a StockRank of 2/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Optimi Health Corp. in?: Optimi Health Corp. (OPTI.CN) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Canada).